drugset / Trial / NCT00890175

Staccato Loxapine Pulmonary Safety in Patients With Asthma

NCT00890175

Phase 1 Completed 52 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.

Timeline

Start
2009-05
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject loxapine Small molecule 10 mg Inhaled

Indications